Locke Lord

Nina Vachhani is an associate in the Chicago office of Locke Lord LLP where she is a member of the Firm’s IP Pharmaceutical and Biotechnology and IP Litigation groups. Nina concentrates her practice on complex patent infringement and other intellectual property litigation matters with a primary emphasis on disputes involving the Hatch-Waxman provisions of the Patent Act and the Federal Food, Drug and Cosmetic Act. Her experience ranges from the pre-litigation stage, including Paragraph IV Certifications, through initial filings, fact and expert discovery, claim construction, pre-trial, trial, and post-trial phases, as well as appeal.

In addition to her Hatch-Waxman practice, Nina also has experience in the seed and agricultural biotechnology industries representing seed producers, seed dealers and distributors, and seedsmen's errors and omissions insurers with regulatory, liability, and transactional matters.

During her undergraduate studies, Nina was a research assistant, where she investigated and co-authored published abstracts on the emotional-somatomotor neural circuits involved in the expression of the physical symptoms of Major Depressive Disorder.

Representative Experience

• Representation of a generic drug manufacturer in Hatch-Waxman litigation involving two patents concerning oral formulations used to treat depression.
• Representation of a generic drug manufacturer in Hatch-Waxman litigation involving a patent concerning injectable formulations used to treat infections.
• Representation of a generic drug manufacturer in Hatch-Waxman litigation involving three patents concerning oral formulations of opioids used to treat pain.
• Representation of a generic drug manufacturer in Hatch-Waxman litigation involving two additional patents concerning oral formulations of opioids used to treat pain.
• Representation of a generic drug manufacturer in Hatch-Waxman litigation involving a patent concerning oral formulations used to treat hyperlipidemia.
• Representation of a generic drug manufacturer in Hatch-Waxman litigation involving sixteen patents concerning oral formulations used to treat hypertriglyceridemia.
• Representation of a generic drug manufacturer in Hatch-Waxman litigation involving three patents concerning topical formulations and medical applicators used to treat hypogonadism.

Professional Affiliations and Recognitions

• Advanced and recognized for top-level copyright brief in 2013 Cardozo/BMI Entertainment and Communications Law Moot Court Competition

Publications

• Clinton SM, Kerman IA, Burghardt PR, Abraham AD, Bedrosian TA, Orr H, Vachhani N, Muzamhindo N, Shabrang C, Beals J, Watson SJ, and Akil H. “Are Emotional-Somatomotor Circuits Modifiable by Exposure to Increased Environmental Complexity?” Washington, DC: Society for Neuroscience, 2008; 38: 283.16.
• Kerman IA, Clinton SM, Burghardt PR, Muzamhindo H, Vachhani N, Shabrang C, Beals J, Akil H, Watson SJ. “Altered wiring of emotional-somatomotor, but not limbic-autonomic, circuits in rat models of depression.” Washington, DC: Society for Neuroscience, 2008; 38: 283.19.